Torrent Pharma
Market cap ₹1.72 L Cr
- P/E
- 76.43
- Day range
- ₹4,476.10 – ₹4,650.70
- 52-week range
- ₹3,532.60 – ₹5,250.00
- Volume
- 3.29 L
- Open
- ₹4,637.90
- Prev close
- ₹4,615.30
Latest results · Q2 FY27(consolidated)Revenue ₹4,979 Cr+50.8%Profit ₹534 Cr-9.6%Margin 10.7%YoY vs the same quarter last year
1 red flag to read up on
- medium
Promoter holding falling
60.78%, down 7.53 pts since 2025-12-31 · 30 Sept 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
TORNTPHARM in NSE indices and F&O
F&O margin for one lot of TORNTPHARM (125 shares)Research profile
Composite 61 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.3%
- Graham no.
- ₹787.42
- vs Graham
- -82.6%
- ROE ÷ P/B
- 2.9%
- 12-1 mom.
- +40.1%
- Return / vol
- 1.31
- Magic Formula
- #533
- Piotroski
- 1/6
- FCF yield
- 1.4%
Appears in 12 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 67 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.19 L Cr | 34.68 | 5.02 | 14.8% | 21.0% | 29.0% | 0.06 | +10.5% |
| Divi's LaboratoriesDIVISLAB | ₹2.38 L Cr | 81.21 | 14.52 | 16.2% | 22.0% | 41.0% | 0.00 | +27.8% |
| Torrent PharmaTORNTPHARM | ₹1.72 L Cr | 76.43 | 9.37 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Zydus LifesciencesZYDUSLIFE | ₹1.13 L Cr | 25.17 | 4.20 | 20.1% | 21.0% | 24.0% | 0.46 | +22.0% |
| Apollo HospitalsAPOLLOHOSP | ₹1.11 L Cr | 53.19 | 11.54 | 22.6% | 17.0% | 16.0% | 0.90 | +20.6% |
| CiplaCIPLA | ₹1.08 L Cr | 32.09 | 3.12 | 11.8% | 15.0% | 17.0% | 0.02 | +2.3% |
| Laurus LabsLAURUSLABS | ₹1.06 L Cr | 97.38 | 20.06 | 18.2% | 18.0% | 32.0% | 0.48 | +29.0% |
| Dr. Reddy's LabsDRREDDY | ₹1.02 L Cr | 36.60 | 2.73 | 11.6% | 13.0% | 11.0% | 0.20 | -5.5% |
| Sector median | ₹23,579 Cr | 41.61 | 5.60 | 15.1% | 17.0% | 25.0% | 0.16 | +20.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 2d agoHeadlines about Torrent Pharma from the last two weeks in the financial press. Stories belong to their publishers; Parasram India does not endorse them.
Key metrics
- P/E (TTM)
- 79.3
- EPS (TTM)
- ₹62.60
- Price / Book
- 9.37
- ROE (FY26)
- 26.8%
- ROCE (latest year)
- 15%
- Dividend yield
- 0.84%
Moving averages (NSE)
- 20-day
- ₹4,704.08
- Price below
- 50-day
- ₹4,840.76
- Price below
- 200-day
- ₹4,493.54
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- FII
- DII
- Public
- Government
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the bonus of 8 Jul 2022: earlier bars are per pre-bonus share.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,732 | 2,745 | 2,859 | 2,889 | 2,809 | 2,959 | 3,178 | 3,302 | 3,303 | 4,197 | 4,921 | 4,979 |
| Expenses | 1,863 | 1,862 | 1,955 | 1,950 | 1,895 | 1,995 | 2,146 | 2,219 | 2,215 | 2,841 | 3,257 | 3,313 |
| Operating Profit | 869 | 883 | 904 | 939 | 914 | 964 | 1,032 | 1,083 | 1,088 | 1,356 | 1,664 | 1,666 |
| OPM % | 32% | 32% | 32% | 32% | 33% | 33% | 32% | 33% | 33% | 32% | 34% | 33% |
| Other Income | 55 | 31 | 24 | -16 | 33 | -42 | -37 | -40 | -23 | -83 | -33 | -20 |
| Interest | 80 | 80 | 75 | 64 | 57 | 56 | 56 | 48 | 45 | 236 | 305 | 300 |
| Depreciation | 213 | 203 | 197 | 198 | 199 | 201 | 201 | 204 | 206 | 508 | 593 | 609 |
| Profit before tax | 631 | 631 | 656 | 661 | 691 | 665 | 738 | 791 | 814 | 529 | 733 | 737 |
| Tax % | 30% | 29% | 30% | 31% | 27% | 25% | 26% | 25% | 22% | 31% | 23% | 28% |
| Net Profit | 443 | 449 | 457 | 453 | 503 | 498 | 548 | 591 | 635 | 364 | 566 | 534 |
| EPS in Rs | ₹13.09 | ₹13.27 | ₹13.50 | ₹13.38 | ₹14.86 | ₹14.71 | ₹16.19 | ₹17.46 | ₹18.76 | ₹10.76 | ₹16.72 | ₹14.04 |
From company filings, updated 25 Oct 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+10 days since Mar 2021
-118 days since Mar 2021
-97 days since Mar 2021
-11 days since Mar 2021
-21 days since Mar 2021
Strengths, risks & growth
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. [1] It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses. [2]
Strengths
- Company is expected to give good quarter
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%
- Company has been maintaining a healthy dividend payout of 57.8%
Risks
- Stock is trading at 9.37 times its book value
- Promoter holding has decreased over last quarter: -7.53%
- The company has delivered a poor sales growth of 11.8% over past five years.
- Company might be capitalizing the interest cost
Compounded Sales Growth
- 10 Years
- +8%
- 5 Years
- +12%
- 3 Years
- +13%
- TTM
- +42%
Compounded Profit Growth
- 10 Years
- +2%
- 5 Years
- +12%
- 3 Years
- +22%
- TTM
- 0%
Stock Price CAGR
- 10 Years
- +19%
- 5 Years
- +24%
- 3 Years
- +33%
- 1 Year
- +26%
Return on Equity
- 10 Years
- +22%
- 5 Years
- +24%
- 3 Years
- +26%
- Last Year
- +27%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 68.31% | 68.31% | 68.31% | 60.78% | -7.53 pp |
| FII | 16.13% | 16.18% | 15.44% | 17.22% | +1.78 pp |
| DII | 9.05% | 8.96% | 9.73% | 13.37% | +3.64 pp |
| Government | 0.10% | 0.00% | 0.10% | 0.09% | -0.01 pp |
| Public | 6.41% | 6.55% | 6.42% | 8.54% | +2.12 pp |
Filed with NSE for Sept 2026: promoters 60.78%, public 39.22% · XBRL filing
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 8.82% (+0.55 pp)- Promoters60.8%
- Foreign institutions17.2%
- Mutual funds8.8%
- Insurance2.0%
- Other domestic institutions2.7%
- Retail4.5%
- Others4.0%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| HDFC Large Cap Fund | 0.88% | 4.09% | +0.33 pp |
| Kotak Mid Cap Fund | 0.48% | 1.25% | +1.25 pp |
| Axis Small Cap Fund | 0.42% | 2.32% | +2.32 pp |
| Kotak Arbitrage Fund | 0.28% | 0.63% | +0.48 pp |
| Axis Large Cap Fund | 0.22% | 1.29% | +0.23 pp |
Scorecard
- Performance
- Avg
- Valuation
- High
- Growth
- Avg
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.
Risk & trend
From 275 daily sessions to 23 Oct 2026.
Risk
- Volatility (1Y)
- 21.7%
- Downside volatility
- 20.6%
- Worst 5% of days
- 2.2%
- Average of that tail
- 2.8%
- Max drawdown (1Y)
- 11.7%
- Below its peak
- 11.7%
Against the market
- Beta vs Nifty 50
- 0.30
- Correlation
- 0.18
- Relative strength (3M)
- -5.4%
- ATR (14)
- 2.4%
Return
- Return 1M
- -8.3%
- Return 3M
- -10.7%
- Return 6M
- +10.8%
- Return 1Y
- +28.5%
- vs 200-day average
- +0.7%
Momentum
- RSI (14)
- 33.9
- MACD histogram
- -10.32
- Stochastic %K
- 16.6
- ADX (14)
- 31.9
- +DI / −DI
- 10.1 / 20.2
- Money flow index
- 20.6
Participation
- Delivery (20d avg)
- 60.6%
- vs its 60-day baseline
- -1.1 pts
- Volume vs 20-day
- +0.1σ
- Close vs day's VWAP
- +0.0%
- 52-week position
- 63 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 31 Mar 2026.
Piotroski F-Score
1 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — failed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — failed
- Asset turnover improving — failed
- Free cash flow
- ₹2,345 Cr
- FCF yield
- 1.4%
- Cash conversion
- 1.41
- Accruals ratio
- -0.020
- Net debt
- ₹13,908 Cr
- Net debt / equity
- 1.66
- EV / sales
- 10.69
- Capex intensity
- 4.8%
- Revenue CAGR
- 41.8%
- Profit CAGR
- -26.9%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Model simulation
30 independent runs of NeoQuasar/Kronos-small, conditioned on daily bars to 9 Oct 2026, simulating 10 sessions ahead.
Lower edge (10th percentile)
₹4,475.04
-3.9%
Upper edge (90th percentile)
₹4,732.4
+1.6%
The marker is the last close, ₹4,656.9. Eight of every ten simulated runs ended inside this range; the middle run ended at ₹4,620.5 (-0.8%), which is the centre of the simulation and not an expected or target price.
The model reads price history only. It has not seen this company's results, its filings, its industry or anything that happened after 9 Oct 2026. Ranges widen with horizon because the further out the simulation runs, the less the recent past constrains it.
Corporate actions
- dividend₹9.00
Dividend - Rs 9 Per Share
29 May 2026ex-date - dividend₹29.00
Interim Dividend - Rs 29 Per Share
18 Feb 2026ex-date - dividend₹6.00
Dividend - Rs 6 Per Share
20 Jun 2025ex-date - dividend₹26.00
Interim Dividend - Rs 26 Per Sh
31 Jan 2025ex-date - dividend₹6.00
Dividend - Rs 6 Per Share
21 Jun 2024ex-date - dividend₹22.00
Interim Dividend - Rs 22 Per Share
12 Feb 2024ex-date - dividend₹8.00
Dividend - Rs 8 Per Share
23 Jun 2023ex-date - dividend₹14.00
Interim Dividend - Rs 14 Per Share
3 Feb 2023ex-date - bonusNot available — not reported in this filing
Bonus 1:1
8 Jul 2022ex-date - dividend₹25.00
Interim Dividend - Rs 25 Per Share
2 Feb 2022ex-date - dividend₹15.00
Dividend - Rs 15 Per Share
17 Jun 2021ex-date - dividend₹20.00
Interim Dividend - Rs 20 Per Share
15 Feb 2021ex-date - dividend₹17.00
Interim Dividend - Rs 17 Per Share Special Dividend - Rs 15 Per Share
18 Mar 2020ex-date - dividend₹4.00
Dividend Rs 4 Per Share
13 Jun 2019ex-date - dividend₹13.00
Interim Dividend - Rs 13 Per Share
6 Feb 2019ex-date - dividend₹5.00
Dividend- Rs 5 Per Share
18 Jun 2018ex-date - dividend₹9.00
Interim Dividend Rs 9/- Per Share (Purpose Revised)
15 Feb 2018ex-date - dividend₹4.00
Dividend - Rs 4/- Per Share
19 Jun 2017ex-date - dividend₹10.00
Interim Dividend Rs 10/- Per Share (Purpose Revised)
10 Feb 2017ex-date - dividend₹15.00
Interim Dividend - Rs 15/- Per Share (Purpose Revised)
16 Mar 2016ex-date
Company announcements
Post Quarterly Financial Result Conference call with investors / analyst
Intimation of Credit Rating
Torrent Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2026 ,inter alia, to consider and approve the Audited Financial ....
Disclosure pursuant to Regulation 30 read with Schedule III of SEBI Listing Regulations
Intimation of Closure of Trading Window Period - Q2
Intimation of Schedule of Investor Meets
Newspaper advertisement in respect of special window for transfer and dematerialisation of physical shares
Outcome of Postal Ballot
Scrutinizer's Report on the Postal Ballot
Intimation of Schedule of Investors Meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
ESG Rating
Newspaper Advertisement for completion of dispatch of Postal Ballot Notice
Notice of Postal Ballot
Transcript of Conference call with Analysts / Investors on Financial Results for the quarter ended 30th June, 2026
Intimation of Cessation of Director of the Company
Filed with BSE (scrip 500420); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Oct 2026Recording
- Jul 2026Transcript
- May 2026TranscriptRecording
- Feb 2026TranscriptRecording
- Nov 2025TranscriptSlidesRecording
- Jul 2025TranscriptSlides
Credit ratings
- Rating update · 7 Oct from fitch
- Rating update · 21 Jul from icra
- Rating update · 5 Jan from icra
- Rating update · 2 Jan from fitch
- Rating update · 6 Oct 2025 from fitch
- Rating update · 8 Jul 2025 from icra
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 24 Oct 2026 (audited). View the source filing. Figures are as filed and are not investment advice.
Torrent Pharma: common questions
Answered from the figures on this page.
